Breaking News Bar

Business News and Information

Positive study data for Bellerophon Therapeutics

Bellerophon Therapeutics LLC (Nasdaq: BLPH) presented positive data from a clinical trial of INOpulse(R) to treat pulmonary arterial hypertension sending the stock price soaring $1.17 to $5.29.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear